The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Side effects of α interferon in chronic hepatitis C
Open accessAbstract
Alpha interferons have been used widely to treat chronic hepatitis C virus infection. These include recombinant interferons, purified natural leukocyte, and lymphoblastoid interferons. Alpha interferon is administered by subcutaneous or intramuscular injection either daily or three times weekly for a period of 6 to as long as 24 months. A wide array of adverse effects of α interferon have been described. Several side effects such as fever, headache fatigue, arthralgias, and myalgias are common, especially with the initial injections. These early side effects of interferon are predictable and are encountered in the majority of patients. These may not require dose modification, but can be problematic for a significant proportion of patients. Other adverse events effects may require dose modification or even discontinuation of therapy in 2% to 10% of patients. Neuropsychiatric side effects such as depression and irritability can be most troublesome; their mechanisms are not well understood. Granulocytes, platelets, and red blood cell counts decrease during treatment, but the decreases are usually mild, although they can be dose limiting if cell counts are low initially. Interferon has important immunomodulatory properties, and treatment can induce autoimmune phenomena, the most frequent being autoimmune thyroiditis with either hypothyroidism or hyperthyroidism, especially in predisposed patients. Other autoimmune disease can be aggravated by interferon therapy. Severe and even life- threatening side effects of interferon occur in 0.1% to 1% of patients; these include thyroid, visual, auditory, renal, and cardiac impairment, and pulmonary interstitial fibrosis. Some of these side effects may be irreversible. Higher doses of interferon (above 5 million units three times weekly) cause higher rates of adverse events than standard doses. Contraindications to α interferon have been recognized.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of Chronic Hepatitis C with Recombinant Interferon Alfa
Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., et al. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911303212203 · Cited by 1,633
Poynard, T., Leroy, V, Cohard, M., Thevenot, T., Mathurin, P., Opolon, P., & Zarski, J. P. (1996) · Hepatology · doi:10.1002/hep.510240405 · Cited by 671
Fattovich, G., Giustina, G., Favarato, S., & Ruol, A. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80184-x · Cited by 489
Side effects of high-dose interferon therapy for chronic hepatitis C
Okanoue, T., Sakamoto, S., Itoh, Y., Minami, M., Yasui, K., Sakamoto, M., Nishioji, K., Katagishi, T., Nakagawa, Y., Tada, H., et al. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80113-9 · Cited by 460
Psychiatric Complications of Long-term Interferon Alfa Therapy
Renault, P. F. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090055011 · Cited by 413
Interferon-Associated Retinopathy
Guyer, D. R. (1993) · Archives of Ophthalmology · doi:10.1001/archopht.1993.01090030068041 · Cited by 282
Clinical Toxicity of the Interferons
Vial, T., & Descotes, J. (1994) · Drug Safety · doi:10.2165/00002018-199410020-00003 · Cited by 269
Clinical Pharmacokinetics of Interferons
Wills, R. J. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199019050-00003 · Cited by 247
Suicide associated with alfa-interferon therapy for chronic viral hepatitis
Janssen, H. L. A., Brouwer, J. T., van der Mast, R. C., & Schalm, S. W. (1994) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80402-7 · Cited by 229
Preziati, D., La Rosa, L., Covini, G., Marcelli, R., Rescalli, S., Persani, L., Del Ninno, E., Meroni, P. L., Colombo, M., & Beck-Peccoz, P. (1995) · European Journal of Endocrinology · doi:10.1530/eje.0.1320587 · Cited by 226
Side Effects of Alpha Interferon
Renault, P., & Hoofnagle, J. (1989) · Seminars in Liver Disease · doi:10.1055/s-2008-1040523 · Cited by 220
Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa
Lisker-Melman, M., Di Bisceglie, A. M., Usala, S. J., Weintraub, B., Murray, L. M., & Hoofnagle, J. H. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90348-3 · Cited by 212
Marazuela, M., García‐Buey, L., González‐Fernández, B., García‐Monzón, C., Arranz, A., Borque, M. J., & Moreno‐Otero, R. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.751768.x · Cited by 211
Antonelli, G., Currenti, M., Turriziani, O., & Dianzani, F. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.4.882 · Cited by 204
Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis
Fabris, P., Floreani, A., Lazzari, F. D., Betterle, C., Greggio, N. A., Naccarato, R., & Chiaramonte, M. (1992) · The Lancet · doi:10.1016/0140-6736(92)91744-s · Cited by 182
INTERFERON-α-INDUCED ACUTE RENAL ALLOGRAFT REJECTION
Magnone, M., Holley, J. L., Shapiro, R., Scantlebury, V., McCauley, J., Jordan, M., Vivas, C., Starzl, T., & Johnson, J. P. (1995) · Transplantation · doi:10.1097/00007890-199504150-00030 · Cited by 178
Mayet, W.-J., Hess, G., Gerken, G., Rossol, S., Voth, R., Manns, M., & ZumBüschenfelde, K.-H. M. (1989) · Hepatology · doi:10.1002/hep.1840100106 · Cited by 173
Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C
García-Buey, L., García-Monzón, C., Rodriguez, S., Borque, M. J., García-Sánchez, A., Iglesias, R., DeCastro, M., Mateos, F. G., Vicario, J., Balas, A., et al. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90139-6 · Cited by 172
Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C
Baudin, É., Marcellin, P., Pouteau, M., Colas-Linhart, N., Floch, J. P. L., Lemmonier, C., Benhamou, J., & Bok, B. D. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb02423.x · Cited by 134
Imagawa, A., Itoh, N., Hanafusa, T., Oda, Y., Waguri, M., Miyagawa, J.-I., Kôno, N., Kuwajima, M., & Matsuzawa, Y. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883851 · Cited by 113
Anterior Ischemic Optic Neuropathy Secondary to Interferon Alfa
Purvin, V. A. (1995) · Archives of Ophthalmology · doi:10.1001/archopht.1995.01100080093034 · Cited by 107
HAZARDS OF INTERFERON THERAPY FOR HBV-SERONEGATIVE CHRONIC HEPATITIS
Vento, S., Perri, G. D., Garofano, T., Cosco, L., Concia, E., Ferraro, T., & Bassetti, D. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91595-x · Cited by 93
Todros, L., Saracco, G. M., Durazzo, M., Abate, M. L., Touscoz, G. A., Scaglione, L., Verme, G., & Rizzetto, M. (1995) · Hepatology · doi:10.1002/hep.1840220506 · Cited by 80
Sudden hearing loss associated with interferon
Kanda, Y., Shigeno, K., Yano, M., Kinoshita, N., Nakao, K., & Matsuo, H. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90237-2 · Cited by 75
The alpha interferons: clinical overview.
Spiegel, R. J. (1987) · PubMed · Cited by 74
Carella, C., Amato, G., Biondi, B., Rotondi, M., Morisco, F., Tuccillo, C., Chiuchiolo, N., Signoriello, G., Caporaso, N., & Lombardi, G. (2008) · Hormone Research · doi:10.1159/000184606 · Cited by 73
Systemic lupus erythematosus in a child receiving long-term interferon therapy
Tolaymat, A., Leventhal, B. G., Şakarcan, A., Kashima, H. K., & Monteiro, C. (1992) · The Journal of Pediatrics · doi:10.1016/s0022-3476(05)80913-8 · Cited by 70
Seizures during alpha interferon therapy
Shakil, A. O., Bisceglie, A. M. D., & Hoofnagle, J. H. (1996) · Journal of Hepatology · doi:10.1016/s0168-8278(96)80185-1 · Cited by 64
Adverse Effects of Interferon on the Cardiovascular System in Patients with Chronic Hepatitis C.
Teragawa, H., 本藤, 達., Amano, H., Hino, F., & Ohbayashi, M. (1996) · Japanese Heart Journal · doi:10.1536/ihj.37.905 · Cited by 62
Occurrence of IDDM during interferon therapy for chronic viral hepatitis
Waguri, M., Hanafusa, T., Itoh, N., Imagawa, A., Miyagawa, J., Kawata, S., Kôno, N., Kuwajima, M., & Matsuzawa, Y. (1994) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(94)90124-4 · Cited by 59
Reversible cognitive decline during high-dose α-interferon treatment
Poutiainen, E. T., Hokkanen, L., Niemi, M., & Färkkilä, M. A. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90294-1 · Cited by 58
Merimsky, O., & Chaitchik, S. (1992) · Anti-Cancer Drugs · doi:10.1097/00001813-199212000-00002 · Cited by 52
Reversible cardiomyopathy induced by interferon.
Sonnenblick, M., Rosenmann, D., & Rosin, A. J. (1990) · BMJ · doi:10.1136/bmj.300.6733.1174 · Cited by 51
Cesare, E. D., Previti, M., Russo, F. P., Brancatelli, S., Ingemi, M. C., Scoglio, R., Mazzù, N., Cucinotta, D., & Raimondo, G. (1996) · Digestive Diseases and Sciences · doi:10.1007/bf02087923 · Cited by 51
Seizures associated with low-dose α-interferon
Janssen, H. L. A., Berk, L., Vermeulen, M., & Schalm, S. W. (1990) · The Lancet · doi:10.1016/0140-6736(90)93356-t · Cited by 49
Primary biliary cirrhosis induced by interferon-α therapy for hepatitis C virus infection
D'Amico, E., Paroli, M., Fratelli, V., Palazzi, C., Barnaba, V., Callea, F., & Consoli, G. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02208992 · Cited by 38
Assessment of interferon cardiotoxicity with quantitative radionuclide angiocardiography
SARTORI, M., Andorno, S., Terra, G. L., POZZOLI, G., Rudoni, M., Sacchetti, G., Inglese, E., & Aglietta, M. (1995) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1995.tb01528.x · Cited by 28
Antonelli, G. (1994) · Antiviral Research · doi:10.1016/0166-3542(94)90070-1 · Cited by 28
Maeda, T., Onishi, S., Miura, T., Iwamura, S., Tomita, A., Saibara, T., & Yamamoto, Y. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02065528 · Cited by 27
Fonseca, V. A., Thomas, M., & Dusheiko, G. M. (1991) · European Journal of Endocrinology · doi:10.1530/acta.0.1250491 · Cited by 26
Self-citationRheumatoid arthritis: a complication of interferon therapy.
Nadir, F., FAGIUOLI, S., Hi, W., Nadir, A., Hopp, E., Gavaler, J. S., & Thiel, D. H. V. (1994) · PubMed · Cited by 21
Increase in triglicerides during α -interferon treatment of chronic viral hepatitis
Ruiz-Moreno, M., Carreno, V., Rua, M. J., Cotonat, T., Serrano, B. C., Santos, M., & Marriott, E. (1992) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80675-0 · Cited by 20
Interferon-related cortical blindness
Merimsky, O., Nisipeanu, P., Loewenstein, A., Reider‐Groswasser, I., & Chaitchik, S. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685955 · Cited by 18
Management of cancer patients receiving interferon alfa-2a
Gauci, L. (1987) · International Journal of Cancer · doi:10.1002/ijc.2910390706 · Cited by 16
Berruti, A., Gorzegno, G., Vitetta, G., Tampellini, M., & Dogliotti, L. (1992) · Tumori Journal · doi:10.1177/030089169207800515 · Cited by 13
Bory, E., Rico, A. G., Pedro-Botet, J. C., & Sola, R. L. (1996) · PubMed · Cited by 4
Cited by
IL-28, IL-29 and their class II cytokine receptor IL-28R
Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., Kuestner, R., Garrigues, U., Birks, C., Roraback, J., et al. (2003) · Nature Immunology · doi:10.1038/ni873 · Cited by 1,570
Davis, G. L., Esteban-Mur, R., Rustgi, V., Hoefs, J., Gordon, S. C., Trepo, C., Shiffman, M. L., Zeuzem, S., Craxi, A., Ling, M.-H., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392102 · Cited by 1,282
Cytokines and the Brain: Implications for Clinical Psychiatry
Kronfol, Z., & Remick, D. G. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.683 · Cited by 784
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Perico, L., Benigni, A., Casiraghi, F., Ng, L. F. P., Renia, L., & Remuzzi, G. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00357-4 · Cited by 607
Host Factors in Coronavirus Replication
de Wilde, A. H., Snijder, E. J., Kikkert, M., & van Hemert, M. J. (2017) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2017_25 · Cited by 546
Metadata
- Authors
- Dusheiko, G.
- Venue
- Hepatology
- Published
- 1997-12
- Volume
- 26
- Issue
- Supplement 3
- Pages
- 112S-121S
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1517770332
- Cited by
- 397
- References
- 46
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.